FDA recommends transitioning away from use of decontaminated disposable respirators

The Food and Drug Administration today urged health care facilities to transition away from using crisis capacity conservation strategies, such as decontamination or bioburden reduction, to extend the use of N95s and other similar disposable respirators.
Due to increased supply of National Institute of Occupational Safety and Health-approved respirators, there is likely to be sufficient supply of respirators available domestically to allow organizations to transition away from decontamination or bioburden reduction and reuse of respirators intended as single use items, FDA notes.
Specifically, FDA recommends:
- Only using decontaminated or bioburden-reduced respirators when there is an insufficient supply of facepiece filtering respirators (FFRs) or the organization is unable to obtain an adequate supply.
- Hospitals and other organizations increase their inventory of available NIOSH-approved respirators, including N95s and other FFRs, elastomerics, and powered air-purifying respirators.
AHA members received a Special Bulletin today on this issue.
Related News Articles
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…